| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -35,957,889 | -5,545,781 |
| Depreciation and amortization | 3,277,569 | - |
| Asset impairment charge | 26,472,407 | - |
| Gain on disposal of property and equipment | 9,674 | - |
| Credit loss expense | 459,233 | 294,034 |
| Depreciation and amortization | - | 2,238,641 |
| Inventory obsolescence | 489,572 | 371,957 |
| Share-based compensation | 3,972,788 | 2,740,343 |
| Noncash lease expense | 446,285 | 359,758 |
| Change in fair value of earnout liabilities | - | 0 |
| Share of losses from equity method investments | -627,732 | -339,090 |
| Back-end fee | 578,901 | 377,490 |
| Paid-in-kind interest | 1,593,416 | 995,244 |
| Accretion of finance liabilities | 120,022 | 86,541 |
| Amortization and write-off of debt issuance costs | 206,363 | 132,821 |
| Accounts receivable, net | 144,959 | -125,086 |
| Accounts receivable related parties | -40,566 | -31,485 |
| Inventory, net | 1,122,497 | 1,130,775 |
| Prepaid and other assets | -318,266 | 76,285 |
| Accounts payable | -359,968 | -42,464 |
| Gain on disposal of property and equipment | - | 9,674 |
| Accounts payable related parties | -3,575 | 1,442 |
| Accrued royalties and expenses | 403,767 | 317,076 |
| Accrued bonuses and commissions | 1,879,615 | -579,389 |
| Operating lease liabilities | -446,372 | -361,513 |
| Net cash provided by (used in) operating activities | 2,841,568 | 665,127 |
| Purchases of property and equipment | 4,543,491 | 3,484,008 |
| Proceeds from disposal of property and equipment | 60,000 | 60,000 |
| Purchases of intangible assets | 23,452 | 23,452 |
| Investment in equity securities | 5,899,524 | 3,538,217 |
| Carepics acquisition | 2,122,146 | 2,122,146 |
| Pay off line of credit | - | 0 |
| Net cash used in investing activities | -12,528,613 | -9,107,823 |
| Loan proceeds, net of debt issuance costs of 228,183 in 2025 and 1,160,740 in 2024 | 12,021,817 | 12,021,817 |
| Pay off debt assumed in carepics acquisition | 1,650,000 | 1,650,000 |
| Net settlement of equity-based awards | -764,421 | -692,672 |
| Cash payment of finance and earnout liabilities | 859,000 | 156,000 |
| Net cash provided by financing activities | 8,748,396 | 9,523,145 |
| Net increase (decrease) in cash | -938,649 | 1,080,449 |
| Cash and cash equivalents at beginning of period | 15,878,295 | - |
| Cash and cash equivalents at end of period | 14,939,646 | - |
Sanara MedTech Inc. (SMTI)
Sanara MedTech Inc. (SMTI)